Sign in Subscribe
Universities and colleges

Altered Expression of Cell Cycle/Apoptosis Regulators Promotes Tumor Progression and Impairs Therapy Response in GIST Patients

Strategic Insights

— 1 min read

Researchers at Leiden University recently conducted a study on the expression of cell cycle/apoptosis regulators in gastrointestinal stromal tumor (GIST) patients to identify potential therapeutic targets and subgroups with different responses to imatinib therapy. The study, published in Clinical Cancer Research, analyzed the expression of 8 key regulators, including p53, p16, p21, CHK2, CCND1, BCL2, CDK4, and MDM12, in 353 histologically validated GIST patients enrolled in a European/Australasian phase III trial. The results revealed frequent impaired expression of BCL2 (78%), CHK2 (53%), p53 (50%), and p16 (47%), with distinct patterns of expression correlating with tumor site, genotype, and progression-free survival (PFS).

Key Takeaways:

  • Impaired expression of BCL2, CHK2, p53, and p16 was observed in 78%, 53%, 50%, and 47% of GIST patients, respectively.
  • Stomach-originating GISTs showed significantly lower expression of p21, p16, and BCL2.
  • KIT/PDGFRA wild-type GISTs had significantly lower expression of CDK4.
  • High p53 expression was associated with low downstream target activation and an independent effect on progression-free survival (PFS).
  • Multivariate analysis showed that p53, p16, BCL2, and CHK2 expression were independent predictors of PFS.
  • Distinct patterns of expression correlated with tumor site, genotype, and PFS.
  • The study suggests that cell cycle/apoptosis maintenance is instrumental for optimal response to imatinib therapy.

Statistics:

  • 353 histologically validated GIST patients analyzed in the study.
  • 78% of GIST patients showed frequent impaired expression of BCL2.
  • 53% of GIST patients showed impaired expression of CHK2.
  • 50% of GIST patients showed impaired expression of p53.
  • 47% of GIST patients showed impaired expression of p16.
  • 88% of high p53 expressers showed low downstream target activation.
  • 16.4% of high p53 expressers harbored a detectable TP53 mutation.

Sources:

  • Romeo, S. et al. (2009). Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 15(12), 4191-4198.
  • Leiden University Medical Center, Department of Pathology, POB 9600, L-1-Q, NL-2300 RC Leiden, Netherlands.
  • American Association for Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.

Read more